NRG-BN013

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Principal Investigator

Ruphesh Kotecha, MD

Status

Disease Site

Brain [BN] Other

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine if the time to local failure is improved with FSRS compared to SRS in patientswith intact (i.e., unresected) brain metastases

Patient Population

Patients must have pathologically proven diagnosis of non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma, or gastrointestinal cancer within 5 years prior to registration. Patients must have at least 1 and up to 8 total intact brain metastases detected on a contrast-enhanced MRI performed ≤ 21 days prior to registration.

 

Target Accrual

269